Rezolute has fully enrolled its Phase 3 upLIFT study for tumor hyperinsulinism, with topline data expected in mid-December. The open-label trial targets a response rate of at least 50% in refractory patients.
Rezolute has fully enrolled its Phase 3 upLIFT study for tumor hyperinsulinism, with topline data expected in mid-December. The open-label trial targets a response rate of at least 50% in refractory patients.